Showing results (11-20 of 28) with videos related to
Sort By:
Pageof 3
European Journal of Cancer (Oxford, England : 1990)|August 7, 2020
Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancerPatricia Martin-Romano, Samy Ammari, Yolla El-Dakdoukti, et al.European Journal of Cancer (Oxford, England : 1990)|September 27, 2021
Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicitiesSamia Hajem, Stéphane Ederhy, Stéphane Champiat, et al.European Journal of Cancer (Oxford, England : 1990)|July 25, 2022
Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trialsPatricia Martin-Romano, Leo Colmet-Daage, Daphne Morel, et al.European Journal of Cancer (Oxford, England : 1990)|March 7, 2020
Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapiesCapucine Baldini, Patricia Martin Romano, Anne-Laure Voisin, et al.JCO Precision Oncology|October 31, 2022
Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine OncologyPatricia Martin-Romano, Laura Mezquita, Antoine Hollebecque, et al.Cancer Research Communications|September 3, 2025
IPH5201, an anti-CD39 monoclonal antibody, as monotherapy or in combination with durvalumab in advanced solid tumorsJohn Powderly, Martina Imbimbo, Antoine Italiano, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin LymphomaAntoine Hollebecque, Stefania Salvagni, Ruth Plummer, et al.Cancer|June 23, 2022
Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignanciesAntoine Hollebecque, Stefania Salvagni, Ruth Plummer, et al.BMJ Supportive & Palliative Care|August 30, 2022
PALLIA 10 score in phase I cancer studiesKaïssa Ouali, Christine Mateus, Arianne Laparra, et al.Pageof 3